Share This Post

BMS enters major deal with NEKTAR for kidney cancer combo

The two- and three-drug combinations will be tested in more than 20 cancer indictions across nine types of cancer — nonsmall cell lung cancer, small cell lung cancer, melanoma, the kidney cancer known as renal cell carcinoma, the urinary tract cancer known as urothelial cell cancer, breast cancer, colorectal cancer, gastric cancer and sarcoma — beginning over the next 14 months. The earliest trials will start this summer.

Read more:

Share This Post

Dena Battle is the President of KCCure. She also serves on the Advisory Board for the Johns Hopkins Sidney Kimmel Cancer Center and as a member of the Patient and Family Advisory Council.

Lost Password


Subscribe for updates!